Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. (Q39034157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

title

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Alina Striha

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Matthew Jenner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

G. C. Cook

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Mark T Drayson

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Faith E Davies

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Kevin D Boyd

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Gareth J Morgan

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

J R Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

D A Cairns

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

W M Gregory

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

C Collett

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

R Sigsworth

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

R Henderson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

M F Kaiser

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

N H Russell

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

C Williams

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

G Pratt

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

B Kishore

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

J Lindsay

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

R G Owen

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

G H Jackson

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

publication date

9 December 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

29 March 2020

http://eprints.whiterose.ac.uk/109657/

content deliverer

White Rose Research Online

0 references

published in

Blood Cancer Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

page(s)

e506

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

29 March 2020

copyright license

start time

1 December 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bcj.2016.114

0 references

cites work

Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients: A Systematic Review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Role of thalidomide in the treatment of patients with multiple myeloma.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Lenalidomide after stem-cell transplantation for multiple myeloma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Improved survival in multiple myeloma and the impact of novel therapies

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

International uniform response criteria for multiple myeloma.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

Multiple myeloma and acute myelomonocytic leukemia

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5223149

A Proportional Hazards Model for the Subdistribution of a Competing Risk

1 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.114

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.114

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.114

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.114

Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27935580

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BCJ.2016.114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

0 references

0 references

Dimensions Publication ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27935580%20AND%20SRC:MED&resulttype=core&format=json